Prostate cancer biomarkers

Current status

Kurt B. Hodges, Emily Bachert, Liang Cheng

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Prostate cancer (PCa) is the second most frequently diagnosed cancer among men worldwide. Given the biological heterogeneity in localized PCa and its variable clinical course, a personalized approach to patient risk stratification and management is needed. A variety of high-throughput technologies, such as next-generation sequencing, transcriptomic, epigenetic, and metabolomic modalities have led to an improved understanding of the genomic basis of PCa and the identification of PCa biomarkers. Novel genomic approaches offer additional information to improve clinical decision making. The goal of this report is to review the use of currently available molecular biomarkers in the diagnosis and prognostication of PCa outcome.

Original languageEnglish (US)
Pages (from-to)353-369
Number of pages17
JournalCritical Reviews in Oncogenesis
Volume22
Issue number5-6
DOIs
StatePublished - Jan 1 2017

Fingerprint

Tumor Biomarkers
Prostatic Neoplasms
Metabolomics
Risk Management
Epigenomics
Biomarkers
Technology
Neoplasms

Keywords

  • DNA
  • Epigenetic signature
  • Gene panel
  • Metabolomics
  • Prostate cancer
  • Proteomics
  • RNA

ASJC Scopus subject areas

  • Cancer Research

Cite this

Prostate cancer biomarkers : Current status. / Hodges, Kurt B.; Bachert, Emily; Cheng, Liang.

In: Critical Reviews in Oncogenesis, Vol. 22, No. 5-6, 01.01.2017, p. 353-369.

Research output: Contribution to journalReview article

Hodges, Kurt B. ; Bachert, Emily ; Cheng, Liang. / Prostate cancer biomarkers : Current status. In: Critical Reviews in Oncogenesis. 2017 ; Vol. 22, No. 5-6. pp. 353-369.
@article{27ae673c349e4f88b1068f095fd271f8,
title = "Prostate cancer biomarkers: Current status",
abstract = "Prostate cancer (PCa) is the second most frequently diagnosed cancer among men worldwide. Given the biological heterogeneity in localized PCa and its variable clinical course, a personalized approach to patient risk stratification and management is needed. A variety of high-throughput technologies, such as next-generation sequencing, transcriptomic, epigenetic, and metabolomic modalities have led to an improved understanding of the genomic basis of PCa and the identification of PCa biomarkers. Novel genomic approaches offer additional information to improve clinical decision making. The goal of this report is to review the use of currently available molecular biomarkers in the diagnosis and prognostication of PCa outcome.",
keywords = "DNA, Epigenetic signature, Gene panel, Metabolomics, Prostate cancer, Proteomics, RNA",
author = "Hodges, {Kurt B.} and Emily Bachert and Liang Cheng",
year = "2017",
month = "1",
day = "1",
doi = "10.1615/CRITREVONCOG.2017020500",
language = "English (US)",
volume = "22",
pages = "353--369",
journal = "Critical Reviews in Oncogenesis",
issn = "0893-9675",
publisher = "Begell House Inc.",
number = "5-6",

}

TY - JOUR

T1 - Prostate cancer biomarkers

T2 - Current status

AU - Hodges, Kurt B.

AU - Bachert, Emily

AU - Cheng, Liang

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Prostate cancer (PCa) is the second most frequently diagnosed cancer among men worldwide. Given the biological heterogeneity in localized PCa and its variable clinical course, a personalized approach to patient risk stratification and management is needed. A variety of high-throughput technologies, such as next-generation sequencing, transcriptomic, epigenetic, and metabolomic modalities have led to an improved understanding of the genomic basis of PCa and the identification of PCa biomarkers. Novel genomic approaches offer additional information to improve clinical decision making. The goal of this report is to review the use of currently available molecular biomarkers in the diagnosis and prognostication of PCa outcome.

AB - Prostate cancer (PCa) is the second most frequently diagnosed cancer among men worldwide. Given the biological heterogeneity in localized PCa and its variable clinical course, a personalized approach to patient risk stratification and management is needed. A variety of high-throughput technologies, such as next-generation sequencing, transcriptomic, epigenetic, and metabolomic modalities have led to an improved understanding of the genomic basis of PCa and the identification of PCa biomarkers. Novel genomic approaches offer additional information to improve clinical decision making. The goal of this report is to review the use of currently available molecular biomarkers in the diagnosis and prognostication of PCa outcome.

KW - DNA

KW - Epigenetic signature

KW - Gene panel

KW - Metabolomics

KW - Prostate cancer

KW - Proteomics

KW - RNA

UR - http://www.scopus.com/inward/record.url?scp=85055960134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055960134&partnerID=8YFLogxK

U2 - 10.1615/CRITREVONCOG.2017020500

DO - 10.1615/CRITREVONCOG.2017020500

M3 - Review article

VL - 22

SP - 353

EP - 369

JO - Critical Reviews in Oncogenesis

JF - Critical Reviews in Oncogenesis

SN - 0893-9675

IS - 5-6

ER -